GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, and EmVenio Research, a patient-focused decentralized trial global organization, today announced a collaboration to deploy a mobile clinical facility in the Claremont, California area to expand GeoVax’s ongoing Phase 2 clinical trial evaluating GEO-CM04S1 as a COVID-19 booster vaccine in healthy patients.
https://finance.yahoo.com/news/geovax-emvenio-announce-collaboration-expand-140000071.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.